Targeting phospholipase D with small-molecule inhibitors as a potential therapeutic approach for cancer metastasis

Future Oncology

Volumn 5, Issue 9, 2009, Pages 1477-1486

  Su, Wenjuan ^a   Chen, Qin ^a   Frohman, Michael A ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Breast cancer; FIPI; Halopemide; Inhibitor; Lipid signaling; Neutrophil chemotaxis; Phospholipase D

Indexed keywords

5 FLUORO 2 INDOLYLDESCHLOROHALOPEMIDE; BETA ACTIN; G PROTEIN COUPLED RECEPTOR; GELATINASE B; HALOPEMIDE; HONOKIOL; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHOLIPASE D; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2; PHOSPHOLIPASE INHIBITOR; PROTEIN KINASE C; RAC1 PROTEIN; RAF PROTEIN; RAPAMYCIN; RHEB PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER INVASION; CANCER RESISTANCE; CANCER SURVIVAL; CELL MOTILITY; CELLULAR DISTRIBUTION; COLORECTAL CARCINOMA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; HUMAN; METASTASIS INHIBITION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM; METASTASIS; NEOPLASM;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHOLIPASE D;

EID: 74949141215     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.110     Document Type: Review

References (77)

1. Mcdermott M, Wakelam MJ, Morris AJ: Phospholipase D. Biochem. Cell Biol.82(1), 225-253 (2004).
2. Mor A, Campi G, Du G et al.: The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane ras via phospholipase D2. Nat. Cell Biol. 9, 712-719 (2007).
3. Zhao C, Du G, Skowronek K, Frohman MA, Bar-Sagi D: Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to ras activation by sos. Nat. Cell Biol. 9, 707-712 (2007). ■ Landmark paper linking phospholipase D2 (PLD2) to direct activation of Ras, a key signaling player in many types of cancer.
4. Delon C, Manifava M, Wood E et al.: Sphingosine kinase 1 is an intracellular effector of phosphatidic acid. J. Biol. Chem. 279(43), 44763-44774 (2004).
5. Ha SH, Kim DH, Kim IS et al.: PLD2 forms a functional complex with MTOR/Raptor to transduce mitogenic signals. Cell. Signal. 18(12), 2283-2291 (2006).
6. Jarquin-Pardo M, Fitzpatrick A, Galiano FJ, First EA, Davis JN: Phosphatidic acid regulates the affinity of the murine phosphatidylinositol 4-phosphate 5-kinase-Ib for phosphatidylinositol-4-phosphate. J. Cell. Biochem. 100(1), 112-128 (2007).
7. Kim JH, Kim JH, Ohba M, Suh PG, Ryu SH: Novel functions of the phospholipase d2-phox homology domain in protein kinase c-z activation. Mol. Cell. Biol. 25(8), 3194-3208 (2005).
8. Foster DA: Phosphatidic acid signaling to MTOR: signals for the survival of human cancer cells. Biochim. Biophys. Acta 91(9), 949-955 (2009). ■ Excellent summary of reports linking PLD activity of pro-survival signals transmitted through the mTOR complex.
9. Du G, Huang P, Liang BT, Frohman MA: Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. Mol. Biol. Cell 15(3), 1024-1030 (2004).
10. Shen Y, Xu L, Foster DA: Role for phospholipase D in receptor-mediated endocytosis. Mol. Cell. Biol. 21(2), 595-602 (2001).
11. Corrotte M, Chasserot-Golaz S, Huang P et al.: Dynamics and function of phospholipase D and phosphatidic acid during phagocytosis. Traffi c 7(3), 365-377 (2006).
12. Iyer SS, Barton JA, Bourgoin S, Kusner DJ: Phospholipases D1 and D2 coordinately regulate macrophage phagocytosis. J. Immunol. 173(4), 2615-2623 (2004).
13. Huang P, Altshuller YM, Chunqiu Hou J, Pessin JE, Frohman MA: Insulin-stimulated plasma membrane fusion of glut4 glucose transporter- containing vesicles is regulated by phospholipase D1. Mol. Biol. Cell 16, 2614-2623 (2005).
14. Waselle L, Gerona RR, Vitale N, Martin TF, Bader MF, Regazzi R: Role of phosphoinositide signaling in the control of insulin exocytosis. Mol. Endocrinol. 19(12), 3097-3106 (2005).
15. Vicogne J, Vollenweider D, Smith J, Huang P, Frohman M, Pessin J: Asymmetric phospholipid distribution drives in vitro reconstituted snare-dependent membrane fusion. Proc. Natl Acad. Sci. USA 103(40), 14761-14766 (2006).
16. Yang J-S, Gad H, Lee S et al.: Copi vesicle fission: a role for phosphatidic acid and insight into golgi maintenance. Nat. Cell Biol. 10, 1146-1153 (2008).
17. Nishikimi A, Fukuhara H, Su W et al.: Sequential regulation of dock2 dynamics by two phospholipids during neutrophil chemotaxis. Science 324, 384-387 (2009). ■■ Landmark paper on the role of PLD in immune cell polarization and migration.
18. Rudge SA, Wakelam MJ: Inter-regulatory dynamics of phospholipase D and the actin cytoskeleton. Biochim. Biophys. Acta 1791(9), 856-861 (2009). ■ Excellent review on the relationship of PLD signaling to cytoskeletal reorganization.
19. Du G, Frohman MA: A lipid-signaled myosin phosphatase surge disperses cortical contractile force early in cell spreading. Mol. Biol. Cell 20, 200-208 (2009).
20. Su W, Yeku O, Olepu S et al.: FIPI, a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 75, 437-446 (2009). ■ First characterization of a small-molecule inhibitor for PLD on cell behaviors such as chemotaxis.
21. Scott SA, Selvy PE, Buck JR et al.: Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat. Chem. Biol. 5(2), 108-117 (2009). ■ Description of isoform-preferential analogs of the PLD small-molecule inhibitor and inhibition of breast cancer migration and invasion.
22. Powner DJ, Pettitt TR, Anderson R, Nash GB, Wakelam MJ: Stable adhesion and migration of human neutrophils requires phospholipase D-mediated activation of the integrin CD11b/CD18. Mol. Immunol. 44(12), 3211-3221 (2007).
23. Huang P, Frohman MA: The potential for phospholipase D as a new therapeutic target. Expert Opin. Ther. Targets 11, 707-716 (2007).
24. Monovich L, Mugrage B, Quadros E et al.: Optimization of halopemide for phospholipase D2 inhibition. Bioorg. Med. Chem. Lett. 17(8), 2310-2311 (2007).
25. Choi SY, Huang P, Jenkins GM, Chan DC, Schiller J, Frohman MA: A common lipid links mfn-mediated mitochondrial fusion and snare-regulated exocytosis. Nat. Cell Biol. 8, 1255-1262 (2006).
26. Katayama K, Kodaki T, Nagamachi Y, Yamashita S: Cloning, differential regulation and tissue distribution of alternatively spliced isoforms of ADP-ribosylation-factordependent phospholipase D from rat liver. Biochem. J. 329(Pt 3), 647-652 (1998).
27. Colley WC, Altshuller YM, Sue-Ling CK et al.: Cloning and expression analysis of murine phospholipase D1. Biochem. J. 326(Pt 3), 745-753 (1997).
28. Zeniou-Meyer M, Zabari N, Ashery U et al.: Phospholipase D1 production of phosphatidic acid at the plasma membrane promotes exocytosis of large dense-core granules at a late stage. J. Biol. Chem. 282(30), 21746-21757 (2007).
29. Du G, Altshuller YM, Vitale N et al.: Regulation of phospholipase D1 subcellular cycling through coordination of multiple membrane association motifs. J. Cell Biol. 162(2), 305-315 (2003).
30. Munck A, Bohm C, Seibel NM, Hashemol Hosseini Z, Hampe W: Hu-k4 is a ubiquitously expressed type 2 transmembrane protein associated with the endoplasmic reticulum. FEBS J. 272(7), 1718-1726 (2005).
31. Santarius M, Lee CH, Anderson RA: Supervised membrane swimming: Small G-protein lifeguards regulate PIPK signalling and monitor intracellular PtdIns(4,5)P2 pools. Biochem. J. 398(1), 1-13 (2006).
32. Cathcart MK: Signal-activated phospholipase regulation of leukocyte chemotaxis. J. Lipid Res. 50(Suppl.) S231-S236 (2009).
33. Chae YC, Kim JH, Kim KL et al.: Phospholipase D activity regulates integrinmediated cell spreading and migration by inducing GTP-rac translocation to the plasma membrane. Mol. Biol. Cell 19(7), 3111-3123 (2008).
34. Lehman N, Di Fulvio M, Mccray N, Campos I, Tabatabaian F, Gomez-Cambronero J: Phagocyte cell migration is mediated by phospholipases PLD1 and PLD2. Blood 108(10), 3564-3572 (2006).
35. Carrigan SO, Pink DB, Stadnyk AW: Neutrophil transepithelial migration in response to the chemoattractant fmlp but not C5a is phospholipase D-dependent and related to the use of CD11b/CD18. J. Leukoc. Biol. 82(6), 1575-1584 (2007).
36. Saito M, Iwadate M, Higashimoto M, Ono K, Takebayashi Y, Takenoshita S: Expression of phospholipase D2 in human colorectal carcinoma. Oncol. Rep. 18(5), 1329-1334 (2007).
37. Wood LD, Parsons DW, Jones S et al.: The genomic landscapes of human breast and colorectal cancers. Science 318(5853), 108-1113 (2007). ■ First identification of driver mutations in PLD2 in the context of breast cancer.
38. Joseph T, Wooden R, Bryant A, Zhong M, Lu Z, Foster DA: Transformation of cells overexpressing a tyrosine kinase by phospholipase D1 and D2. Biochem. Biophys. Res. Commun. 289(5), 1019-1024 (2001).
39. Ahn BH, Kim SY, Kim EH et al.: Transmodulation between phospholipase D and c-src enhances cell proliferation. Mol. Cell. Biol. 23(9), 3103-3115 (2003).
40. Lu Z, Hornia A, Joseph T et al.: Phospholipase D and RalA cooperate with the epidermal growth factor receptor to transform 3y1 rat fibroblasts. Mol. Cell. Biol. 20(2), 462-467 (2000).
41. Min DS, Kwon TK, Park WS et al.: Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts. Carcinogenesis 22(10), 1641-1647 (2001).
42. Samuels ML, Mcmahon M: Inhibition of platelet-derived growth factor- and epidermal growth factor-mediated mitogenesis and signaling in 3t3 cells expressing d raf-1:Er, an estradiol-regulated form of raf-1. Mol. Cell. Biol. 14(12), 7855-7866 (1994).
43. Kerkhoff E, Rapp UR: Cell cycle targets of ras/raf signalling. Oncogene 17(11 Reviews), 1457-1462 (1998).
44. Joseph T, Bryant A, Frankel P et al.: Phospholipase D overcomes cell cycle arrest induced by high-intensity raf signaling. Oncogene 21(22), 3651-3658 (2002).
45. Zhong M, Shen Y, Zheng Y, Joseph T, Jackson D, Foster DA: Phospholipase D prevents apoptosis in v-src-transformed rat fibroblasts and mda-mb-231 breast cancer cells. Biochem. Biophys. Res. Commun. 302(3), 615-619 (2003).
46. Nozawa Y: Roles of phospholipase D in apoptosis and pro-survival. Biochim. Biophys. Acta 1585(2-3), 77-86 (2002).
47. Kim KO, Lee KH, Kim YH, Park SK, Han JS: Anti-apoptotic role of phospholipase D isozymes in the glutamate-induced cell death. Exp. Mol. Med. 35(1), 38-45 (2003).
48. Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mtor pathway. Curr. Opin. Cell Biol. 17(6), 596-603 (2005).
49. Tee AR, Blenis J: Mtor, translational control and human disease. Semin. Cell Dev. Biol. 16(1), 29-37 (2005).
50. Veverka V, Crabbe T, Bird I et al.: Structural characterization of the interaction of MTOR with phosphatidic acid and a novel class of inhibitor: compelling evidence for a central role of the frb domain in small moleculemediated regulation of mtor. Oncogene 27(5), 585-595 (2008).
51. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J: Phosphatidic acidmediated mitogenic activation of MTOR signaling. Science 294(5548), 1942-1945 (2001).
52. Chen Y, Rodrik V, Foster DA: Alternative phospholipase d/MTOR survival signal in human breast cancer cells. Oncogene 24(4), 672-679 (2005).
53. Hui L, Abbas T, Pielak RM, Joseph T, Bargonetti J, Foster DA: Phospholipase D elevates the level of mdm2 and suppresses DNA damage-induced increases in p53. Mol. Cell. Biol. 24(13), 5677-5686 (2004).
54. Sun Y, Fang Y, Yoon MS et al.: Phospholipase D1 is an effector of Rheb in the mtor pathway. Proc. Natl Acad. Sci. USA 105(24), 8286-8291 (2008).
55. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA: Regulation of MTORC1 and MTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol. Cell. Biol. 29(6), 1411-1420 (2009).
56. Nguyen DX, Bos PD, Massague J: Metastasis: from dissemination to organspecific colonization. Nat. Rev. 9(4), 274-284 (2009).
57. Honda A, Nogami M, Yokozeki T et al.: Phosphatidylinositol 4-phosphate 5-kinase a is a downstream effector of the small G protein arf6 in membrane ruffle formation. Cell 99(5), 521-532 (1999).
58. Shen Y, Zheng Y, Foster DA: Phospholipase D2 stimulates cell protrusion in v-srctransformed cells. Biochem. Biophys. Res. Commun. 293(1), 201-206 (2002).
59. Zheng Y, Rodrik V, Toschi A et al.: Phospholipase D couples survival and migration signals in stress response of human cancer cells. J. Biol. Chem. 281(23), 15862-15868 (2006).
60. Knoepp SM, Chahal MS, Xie Y et al.: Effects of active and inactive phospholipase D2 on signal transduction, adhesion, migration, invasion, and metastasis in el4 lymphoma cells. Mol. Pharmacol. 74(3), 574-584 (2008).
61. Kang DW, Park MH, Lee YJ et al.: Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/RAS/ERK/NFkB-dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J. Biol. Chem. 283(7), 4094-4104 (2008).
62. Park MH, Ahn BH, Hong YK, Min do S: Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/Nf-kB/SP1-mediated signaling pathways. Carcinogenesis 30(2), 356-365 (2009).
63. Lukowski S, Mira JP, Zachowski A, Geny B: Fodrin inhibits phospholipases A2, C, and D by decreasing polyphosphoinositide cell content. Biochem. Biophys. Res. Commun. 248(2), 278-284 (1998).
64. Chung JK, Sekiya F, Kang HS et al.: Synaptojanin inhibition of phospholipase D activity by hydrolysis of phosphatidylinositol 4,5-bisphosphate. J. Biol. Chem. 272(25), 15980-15985 (1997).
65. Lee C, Kim SR, Chung JK, Frohman MA, Kilimann MW, Rhee SG: Inhibition of phospholipase D by amphiphysins. J. Biol. Chem. 275(25), 18751-18758 (2000).
66. Venable ME, Bielawska A, Obeid LM: Ceramide inhibits phospholipase D in a cell-free system. J. Biol. Chem. 271(40), 24800-24805 (1996).
67. Abousalham A, Liossis C, O'Brien L, Brindley DN: Cell-permeable ceramides prevent the activation of phospholipase D by ADP-ribosylation factor and RhoA. J. Biol. Chem. 272(2), 1069-1075 (1997).
68. Yoshimura S, Sakai H, Ohguchi K et al.: Changes in the activity and mRNA levels of phospholipase D during ceramide-induced apoptosis in rat c6 glial cells. J. Neurochem. 69(2), 713-720 (1997).
69. Garcia A, Zheng Y, Zhao C et al.: Honokiol suppresses survival signals mediated by ras-dependent phospholipase D activity in human cancer cells. Clin. Cancer Res. 14(13), 4267-4274 (2008).
70. Pannequin J, Delaunay N, Darido C et al.: Phosphatidylethanol accumulation promotes intestinal hyperplasia by inducing zonabmediated cell density increase in response to chronic ethanol exposure. Mol. Cancer Res. 5(11), 1147-1157 (2007).
71. Lewis JA, Scott SA, Lavieri R et al.: Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for pld1 specificity. Bioorg. Med. Chem. Lett. 19(7), 1916-1920 (2009).
72. Lavieri R, Scott SA, Lewis JA et al.: Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II. Identification of the 1,3,8-triazaspiro[4,5] decan-4-one privileged structure that engenders PLD2 selectivity. Bioorg. Med. Chem. Lett. 19(8), 2240-2243 (2009).
73. Uchida N, Okamura S, Nagamachi Y, Yamashita S: Increased phospholipase D activity in human breast cancer. J. Cancer Res. Clin. Oncol. 123(5), 280-285 (1997).
74. Noh DY, Ahn SJ, Lee RA et al.: Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett. 161(2), 207-214 (2000).
75. Yamada Y, Hamajima N, Kato T et al.: Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer. J. Mol. Med. 81(2), 126-131 (2003).
76. Uchida N, Okamura S, Kuwano H: Phospholipase D activity in human gastric carcinoma. Anticancer Res. 19(1B), 671-675 (1999).
77. Zhao Y, Ehara H, Akao Y et al.: Increased activity and intranuclear expression of phospholipase d2 in human renal cancer. Biochem. Biophys. Res. Commun. 278(1), 140-143 (2000).